Current options and future perspectives in the treatment of dyslipidemia

HIGHLIGHTS

SUMMARY

[106] Mipomersen leading to leading decrease Mipomersen mRNA mRNA leading to decrease Medium decrease of LDL-C Used for thetreatment treatment of FH Medium decrease LDL-C Used for the of Used for71% theoftreatment of FH up to 71% upcombination to Lomitapide production duced lipoprotein production [106] Medium decrease of LDL-C MTP inhibitor leading to reduced Medium decrease of LDL-C Medium decrease of LDL-C levels up LDL-C to 30% ezetimibe LDL-C was re(especially of Apo B) Mipomersen mRNA leading toApo decrease Mipomersen mRNA leading to decrease was re . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or E-mail:

If you don't have an account, you can create one here.